|Videos|July 7, 2022
Safety of Cemiplimab for Basal Cell Carcinoma
Author(s)Jennifer L. Atlas, MD, Shahab Babakoohi, MD
Experts review the safety and toxicity data of anti-PD-1 antibody agent cemiplimab for basal cell carcinoma treatment.
Advertisement
Advertisement
Related to this article
Adding intismeran autogene to pembrolizumab cut the risk of recurrence and distant metastasis in resected high-risk melanoma in INTerpath-001.
Phase 1 data support continued investigation of roginolisib in advanced cancers, including metastatic uveal melanoma.
Advertisement
Advertisement
Trending on OncLive
1
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
4
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
5